Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody
James Araujo, Marcel Zocher, Kristin Wallace et al. · Journal of Pharmaceutical and Biomedical Analysis · 2011
Cited by 30 works. doi:10.1016/j.jpba.2011.03.008
Authors
References
- The Immunopathology of Joint Inflammation in Rheumatoid Arthritis
- High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR
- Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
- Therapeutic antibodies for autoimmunity and inflammation
- Increased clearance of IgG in mice that lack β2‐microglobulin: possible protective role of FcRn
- Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
- Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
- Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis.
- Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody—antigen interaction